EGFR and glioblastoma: Focusing on the detailed clinical characterization of these side effects, our group have recently reported, for the first time, the CCM analysis of corneal side effects secondary to the use of ABT-414 in a cohort of patients affected by EGFR-amplified recurrent GBM (15).